Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Low Dose Ketamine Infusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be eligible if they meet the following criteria:~* Children age one three (3) years to eighteen (18) years, requiring admission to the Pediatric ICU, who require intubation for respiratory failure and continuous infusion fentanyl.~* Patients of both genders, all races and ethnic backgrounds will be eligible.~* Patients will need to have AST and ALT evaluated within the two weeks prior to enrollment, with the result being within two times the normal range. Patients who have not had AST and ALT evaluated within two weeks will have to be evaluated prior to enrollment. Serum will be evaluated for AST and ALT when convenient to other lab testing prior to enrollment.~* Patients meeting the above criteria will be eligible regardless of nutritional status, performance status or recovery from prior medical treatment.~* Patients will not be excluded if they require simultaneous infusions of sedation with benzodiazepine.~* Enrollment will require parental consent.~Exclusion Criteria:~* Patients will not be eligible if they meet any of the following criteria:~* Patients who are currently on oral analgesia or sedation~* Patients who have a prior history of drug or alcohol dependence/abuse.~* Patients who are allergic to opioids.~* Patients who are allergic to ketamine or any NMDA antagonist. Patients in whom significant elevation of blood pressure would constitute a serious hazard~* Patients with documented or clinical concern for elevated intracranial pressure.~* Patients with known liver dysfunction as evidenced by AST and ALT two times the normal limit within the past two weeks.~* Patients who are being medically paralyzed as part of their current treatment.~* Patients with any underlying neurologic condition, or impairment, which would interfere with their perception of, or response to, pain or discomfort.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Ketamine will be administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to in PICU patients that meet eligibility criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).